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Abstract A good understanding of the in vivo pharmacokinetics of radioligands is
important for accurate PET quantification in molecular brain imaging. For many
reversibly binding radioligands for which there exists a brain region devoid of
molecular target binding sites called “reference tissue,” data analysis methods that
do not require blood data including the standardized uptake value ratio of target-to-
reference tissue at a “fixed time point” (SUVR) and reference tissue model to
estimate binding potential (BPND) are commonly used, the latter being directly
proportional to the binding site density (Bavail). Theoretically, BPND is the tissue
ratio minus 1 at equilibrium. It is generally believed that radioligands should not
ideally produce radiometabolites that can enter the brain because they might
complicate accurate quantification of specific binding of the parent radioligand.
However, the tissue ratio that contains the contribution of radiometabolite can also
be theoretically a valid parameter that reflects the target binding site density. This
article describes the validation of the tissue ratio concept using, as an example of
our recent PET data analysis approach for a novel radioligand, 11C-PBB3, to
quantify pathological tau accumulations in the brain of Alzheimer’s disease patients
in which the SUVR and reference tissue model methods using the cerebellar cortex
as the reference tissue were validated by the dual-input graphical analysis model
that uses the plasma parent and radiometabolite activity as input functions in order
to take into account the contribution of the radiometabolite entering the brain.
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17.1 Introduction
Molecular brain imaging with positron emission tomography (PET) using
radiolabeled ligands (radioligands) that target neuroreceptors/transporters and neu-
ropathological biomarker proteins such as amyloid β (Aβ) proteins and pathological
tau proteins has many exciting clinical and research applications. The major
advantage of PET imaging is that PET using suitable radioligands allows for the
accurate quantification of the target binding site density. For accurate PET quanti-
fication, however, a good understanding of the in vivo pharmacokinetics of
radioligands is important.
For many reversibly binding radioligands for which there exists a brain region
devoid of molecular target binding sites called “reference tissue,” data analysis
methods that do not require blood data including the standardized uptake value ratio
(SUVR) method and reference tissue models to estimate binding potential (BPND)
are commonly used to quantify specific molecular target binding sites. The validity
of these simple methods can be evaluated by detailed pharmacokinetic modeling of
dynamically acquired PET data and radiometabolite corrected arterial plasma
parent radioligand activity as an input function. In this respect, it is generally
believed that radioligands should not ideally produce metabolites that can enter
the brain because they might complicate accurate quantification of specific binding
of the parent radioligand.
The purpose of this article is to show that PET quantification using the SUVR
and reference tissue model methods can also be valid even when the metabolite
contributes to the measured brain radioactivity. In the theory section, the concept of
PET measured “brain tissue ratios” in the context of radiometabolites entering the
brain will be explored first, and then our recent PET data analysis approach for a
novel radioligand, 11C-PBB3 (2-((1E,3E)-4-(6-(11C-methylamino)pyridin-3-yl)
buta-1,3-dienyl) benzo[d]thiazol-6-ol) [1], to quantify pathological tau accumula-
tions in the brain of Alzheimer’s disease (AD) [2] will be highlighted as an example
in which the SUVR and reference tissue model methods were validated by the dual-
input graphical analysis model [3] that takes into account the contribution of the
radiometabolite entering the brain.
17.2 Materials and Methods
17.2.1 Theory
PET data in molecular brain imaging are commonly analyzed by applying kinetic
compartment models, which assume a compartmental system and derive the target
binding parameters that reflect the densities of target binding sites in brain regions
of interest (ROIs) [4]. Brain regions containing target binding sites (target tissue)
have at least three compartments (or two-tissue (2T) compartments) (Fig. 17.1a
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top). The first compartment is the arterial plasma (Ca), from which the
unmetabolized parent radioligand passes into the second compartment or the first
tissue compartment known as the nondisplaceable compartment (CND). The third
compartment or the second tissue compartment (CS) is the specific target binding
sites. Reference tissue regions do not have the specific binding compartment (CS)
(Fig. 17.1a bottom). In Fig. 17.1a, K1 (mLmL1min1) is the delivery rate
constant; k2 (min
1), k3 (min
1), and k4 (min
1) are the first-order kinetic rate
constants. Throughout the text, the prime sign is used to indicate the reference
tissue. CB tð Þ ¼ CND tð Þ þ CS tð Þ and C0BðtÞ ¼ C
0
NDðtÞ represent the target and refer-
ence tissue time activity, respectively, and Ca(t) is the plasma parent radioligand
activity at time t after the bolus radioligand administration.
Using Ca(t) as an input function, compartment model approaches allow for the
estimation of the distribution volume, V, which is the brain-to-plasma radioactivity
ratio, CB(t)/Ca(t), at equilibrium in which there is no net transfer of radioligand
activity between all compartments. Of note is that this equilibrium condition cannot
be achieved in the PET experimental paradigm with a bolus radioligand adminis-
tration. However, the compartment model analysis allows for the estimation of
parameters defined at equilibrium. By assuming that the nondisplaceable distribu-
tion volume in the target tissue (VND) is the same as in the reference tissue (V
0
ND),
the target binding parameter, binding potential (BPND), is calculated as
V  V 0=V 0 ¼ VS=VND, which is directly proportional to the binding site density
Bavail, i.e., BPND ¼ fND Bavail=KDð Þ, where fND and KD represent the fraction of
Fig. 17.1 Compartment configurations used to model in vivo radioligand kinetics when the parent
only enters the brain (a) and both the parent and metabolite enter the brain (b). Terms are defined
in the text
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nondisplaceable compartment from which the radioligand can exchange with the
specifically bound compartment (free tissue fraction) and the equilibrium dissoci-
ation constant for radioligand-binding site complex, respectively [5]. The above
relationship between BPND and Bavail is derived from the principle used in in vitro
binding assays, which is in turn based on the bimolecular enzymatic reaction
described by Michaelis and Menten [6]. Of note is that BPND can also be expressed
as



















where t represents the time at which the compartment system is in equilibrium.
BPND is, therefore, equivalent to the tissue ratio minus 1 at equilibrium.
Reference tissue models derived from the above compartment model estimate
BPND by using C
0
B(t) as an input function without requiring arterial plasma data
(Ca(t)) [4]. On the other hand, SUVR is the target-to-reference tissue ratio measured
at a “fixed time point” after the bolus radioligand administration. The advantage of
SUVR is that it can be calculated from static PET imaging data without the
requirement of arterial data. SUVR ¼ CB tð Þ=C0B tð Þ is, therefore, closely related to
BPND (Eq. 17.1), the differences between the two being that BPND is independent of
radioligand delivery (blood flow) or its systemic clearance because it is defined at
equilibrium,
On the other hand, in the situation where the metabolite enters the brain, the
compartment system is more complex as shown in Fig. 17.1b in which superscripts
P and M refer to “parent” and “metabolite,” respectively, and the metabolite is
assumed not to bind specifically to targets (see the discussion about the situation
where the metabolite also binds specifically) [3]. Here, let’s consider the tissue ratio
minus 1 at equilibrium assuming that VND is the same in the reference and target
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0P þ δV 0M
 1
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V PND þ δVMND
ð17:2Þ
where δ is the metabolite-to-parent activity ratio in plasma at equilibrium
δ ¼ CMa tð Þ=CPa tð Þ
 
and it is a constant value. This tissue ratio minus 1 at equilib-
rium has an additional term, δVMND, the contribution of the metabolite
nondisplaceable distribution volume in the denominator of Eq. 17.2, and it is here
denoted by BP*ND to distinguish it from BPND, which is the tissue ratio minus 1 at
equilibrium when only the parent enters the brain. To estimate this tissue ratio
minus 1 by the reference tissue model, in fact, no knowledge of the metabolite
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status is needed because it uses CB tð Þ as an input function. The same argument
applies to the SUVR. Importantly, BP*ND like BPND is directly proportional to the
target binding site density, Bavail, as shown below.
BP*ND ¼
VS











where f PP or f
M
P the free fraction of parent (P) or metabolite (M) in plasma is a
constant and so are f PND, f
M
ND, and δ in the same individual. Note that VS ¼ f PPBavail
=KD and VND can be expressed as fP/fND because the free radioligand or metabolite
activity in the plasma and the tissue compartments are the same at equilibrium
f PCa tð Þ ¼ fNDCND tð Þð Þ [4, 5]. The validation of the reference tissue model BPND
can be accomplished by the dual-input graphical analysis model derived from the
model illustrated by Fig. 17.1b that takes into account the contribution of
radiometabolites entering the brain using the combined plasma radioactivity
CPa tð Þ þ CMa tð Þ
 




CB tð Þ ¼ α tð Þ
ð t
0
CPa tð Þ þ CMa tð Þ
 
dt
CB tð Þ þ β tð Þ ð17:4Þ
Eq. 17.4 becomes linear when the system reaches transient equilibrium between the
brain and plasma compartments at time t* and both the slope α and intercept β can








The tissue ratio minus 1 at equilibrium can also be estimated by the traditional
compartment model (Fig. 17.1a) using the parent-only input function (CPa (t)) if data
fitting can be adequately accomplished. However, it may not match the tissue ratio
minus 1 estimated by the reference tissue model or the dual-input model if a
significant amount of the metabolite is entering the brain because the tissue
radioactivity includes the metabolite contribution, which is not accounted for by
the traditional compartment model (Fig. 17.1a).
17.2.2 Radioligand
11C-PBB3 is a novel radioligand developed at the National Institute of Radiological
Sciences, Chiba, Japan, for PET imaging of pathological tau aggregates in the brain
[1]. Neurofibrillary tau tangles are one of the two pathological hallmarks of AD, the
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other being the senile plaques containing Aβ deposition [7]. 11C-PBB3 binds
reversibly to neurofibrillary tau tangles of a wide range of isoform compositions
with high affinity (KD¼ 2.5 nM) and selectivity [1]. 11C-PBB3 upon intravenous
administration is rapidly converted in plasma to one major radiometabolite identi-
cal chemically in both humans and mice, a significant amount of which enters the
mouse brain (30% of radioactivity in brain 5 min after injection) [8]. 11C-PBB3
SUVR in AD patients has previously been shown to reflect the known pathological
tau distribution at various stages of AD [9].
17.2.3 PET Data
The reader is referred to our recent 11C-PBB3 PET data analysis study [2] regarding
the detail of PET data acquisition and full data analysis. Here, the description is
limited to information relevant to illustrating the concept of tissue ratio estimation
considering the contribution of radiometabolite to the brain activity.
11C-PBB3 PET data consisted of 70 min dynamic scans after a bolus injection of
approximately 400 MBq of 11C-PBB3 in 7 AD patients (76 7 y) and 7 elderly
healthy control subjects (70 6 y). Input functions (CPa (t) and CMa (t)) were obtained
from multiple arterial samples by determining plasma fractions of the parent and its
radiometabolites with high-performance liquid chromatography.
To improve the statistical quality of PET ROI data, we generated cerebral
cortical ROIs pooling all voxels of high (>0.3, high), medium (0.15–0.3, middle),
low (0–0.15, low), and non-binding (<0) BP*ND values on preliminarily generated
parametric images by the original multilinear reference tissue model (MRTMO)[10]
using the cerebellar cortex as the reference tissue because tau accumulation is
known to be histopathologically absent in the cerebellar cortex of either normal
or AD brains [11].
17.2.4 Data Analysis
The tissue ratio minus 1 was estimated in four ways using cerebral cortical ROI data
with the cerebellar cortex as the reference tissue:
1) BPND estimation by the dual-input graphical analysis using C
P
a tð Þ þ CMa tð Þ
 
as
an input function (Eq. 17.4)
2) BPND estimation by 2T compartment kinetic analysis using C
P
a (t) as an input
function (Fig. 17.1a)
3) BPND estimation by the reference tissue model MRTMO using C
0
B(t) as an input
function
4) SUVR minus 1 at a fixed time point (50 min–70 min)
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The tissue ratio minus 1 values obtained by the above 4 methods were then
compared to validate the use of SUVR and the reference tissue model BPND.
Additionally, parametric images of MRTMO and (SUVR-1) were generated and
compared.
17.3 Results
The brain 11C-PBB3 time activity curves (TACs) quickly peaked within a few
minutes of intravenous injection of 11C-PBB3 with gradual decreases thereafter
with a significantly slower washout for high binding cerebral cortex in ADs than in
HCs (Fig. 17.2a). Plasma parent TACs peaked very quickly and decreased also
quickly thereafter (Fig. 17.2b). One major radiometabolite of 11C-PBB3 appeared
very quickly in the plasma and slowly decreased thereafter (Fig 17.2b). Both
plasma parent and metabolite TACs in ADs and HCs were very similar (Fig. 17.2b)
Graphical plots (Eq. 17.4) with a combinedCPa tð Þ þ CMa tð Þ plasma input became
linear beyond t*¼ 11 min when both α and β could be considered constant. BPND
estimations were very stable for all regions. On the other hand, the 2T kinetic
analysis to estimate BPND was unstable in some regions with a large parameter
estimation variability in the rest of the regions. The 2TC BPND values were
numerically quite different from the corresponding BPND values with a very poor
correlation between the two-tissue ratio minus 1 estimations (BPND ¼ 1:06 0:66
vs. BP*ND ¼ 0:36 0:07 with r2¼ 0.04 in the high binding region, for example.
The reference tissue model MRTMO robustly estimated BP
*
ND for the ROI data
and enabled stable voxel-wise parametric imaging ofBP*ND. TheBP
*
ND estimated by
the ROI-based MRTMO analysis closely matched the corresponding BP

ND
Fig. 17.2 Time activity curves (TACs) in the brain (a) and arterial plasma (b) after the injection of
11C-PBB3 in AD patients and healthy controls (HCs). (a) TACs are shown for the high tau binding
(~) cerebral cortical region and cerebellar cortex (◆) in ADs, and the cerebral cortical region (△)
and the cerebellar cortex (◇) in HCs. (B) Plasma TACs are shown for the total radioactivity (thick
(ADs) and thin (HCs) solid lines), metabolite (thick (ADs) and thin (HCs) dotted lines), and parent
(thick (ADs) and thin (HCs) dashed lines). Data represent mean of all 7 ADs or 7 HCs
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estimated by the dual-input graphical analysis with a perfect correlation between
the two (r2¼ 1.00) (Fig. 17.3a). On the other hand, SUVR minus 1 values (calcu-
lated from the averaged 50 min to 70 min data) overestimated MRTMO BP

ND
values by up to 38%. However, there was an excellent correlation between the two
(r2¼ 0.97) (Fig. 17.3b). Both the MRTMO BPND parametric images and SUVR
minus 1 images showed a clear delineation of tau pathology in the cerebral cortices
including the hippocampal formation in AD (Fig. 17.4a, c) compared with HC
(Fig. 17.4b, d).
17.4 Discussion
In the present article, we have shown that the reference tissue model-based binding
potential (BPND) that reflects the target binding site density (Bavail) is theoretically
equivalent to the tissue ratio minus 1 at equilibrium, whereas closely related SUVR
minus 1 is the tissue ratio minus 1 at a fixed time point after the bolus radioligand
administration. We have shown that the tissue ratio minus 1 at equilibrium (BPND)
also reflects Bavail even in the situation where the radiometabolite enters the brain.
The definition of binding potential, BPND, therefore can be extended to this
situation (expressed as BPND here). The validity of the reference tissue model
BPND and SUVR, both of which do not require arterial plasma data, can be
evaluated by the dual-input CPa tð Þ þ CMa tð Þ
 
model but not by the conventional
single input (CPa (t)) model because the tissue ratio minus 1 at equilibrium includes
the radiometabolite contribution to the tissue activity, which is not accounted for by
the parent-only model. Of note is that the reference tissueBP*ND or SUVR estimation
Fig. 17.3 (a) Correlation of ROI BP*ND estimated by dual-input graphical model and reference
tissue model MRTMO. (b) Correlation of ROI BP
*
ND estimated by MRTMO and SUVR minus
1 (50 min–70 min)
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does not require any assumption of metabolite, because the estimation is performed
without blood data.
Although we assumed here that the radiometabolite does not bind to the target
site, it can be shown that BPND is also directly proportional to Bavail when the
metabolite binds specifically (17.2). BPND has additional term, δV
M
ND, in the denom-
inator (Eq. 17.2), which may increase the intersubject variability of BPND compared
with BPND. In our
11C-PBB3 analyses, there was no difference in the mean
V PND þ δVMND
 
values between ADs and HCs [2].
SUVR minus 1 at 50 min–70 min overestimated BPND. However, there was an
excellent correlation between the two. SUVR is potentially affected by blood flow
and systemic radioligand clearance, while BPND is independent of these factors
because BPND represents the tissue ratio minus 1 at equilibrium. Therefore, a larger
variability of cerebral blood flow in AD patents than in normal elderly subjects may
result in a larger intersubject SUVR variability compared with BPND, although a
longer dynamic imaging needed for BPND estimation might be less well tolerated
for elderly patients than a shorter static imaging for SUVR measurements. The
advantage of the reference tissue model-based estimation of the tissue ratio over the
SUVR measurement has recently been shown for a long-term longitudinal Aβ PET
imaging study [12].
Fig. 17.4 Coronal parametric images of AD and HC. The MRTMO BP
*
ND images in ADs (a) and
HCs (b). SUVR-1 images (50 min–70 min) in ADs (c) and HCs (d)
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17.5 Conclusions
The reference tissue-based binding potential (BPND) that reflects the target binding
site density (Bavail) is equivalent to the tissue ratio minus 1 at equilibrium. The
tissue ratio minus 1 at equilibrium (BPND) also reflects Bavail even in the situation
where the radiometabolite enters the brain. The validity of the reference tissue
model BPND and SUVR can be evaluated by the dual-input model not by the
conventional single input model because the tissue ratio minus 1 at equilibrium
includes the radiometabolite contribution to the tissue activity, which is not
accounted for by the parent-only model.
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